Monoclonal Antibody Platform for Fibrosis-Related Diseases
Driving innovations in a field of diagnostics and treatment of chronic kidney disease, cardiovascular disease, trauma shock and preeclampsia.
Platform video
patented anti-MBG monoclonal antibody clones
Based on 30+ years of clinical experience
Keywords
Search themes around MBG and fibrosis.
marinobufagenin anti-MBG antibody CKD fibrosis Na+/K+-ATPase vascular stiffness MBG biomarker immunoadsorption preeclampsia hemorrhagic shock microcirculation vasoconstriction cardiotonic steroid (CTS)
Padakonn Pharma platform video
Product platform
Blocking MBG. Slowing fibrosis.
Padakonn is developing anti-MBG hemoperfusion filters designed to selectively bind and neutralize marinobufagenin (MBG), an endogenous cardiotonic steroid linked to fibrosis and vascular dysfunction. The platform combines patented monoclonal antibody technology with established dialysis infrastructure, creating a practical pathway toward targeted intervention in fibrosis-related diseases.
Fast-acting anti-MBG monoclonal antibodies
Compatible with existing dialysis workflows
Focused on fibrosis and vascular dysfunction
Restore sodium-potassium balance
Research
MBG, fibrosis and vascular dysfunction.
Research Areas: Chronic Kidney Disease, Cardiovascular Disease, Preeclampsia, Hemorrhagic Shock
MBG biology
Endogenous cardiotonic steroids
Padakonn Pharma develops monoclonal antibodies targeting Marinobufagenin (MBG), an endogenous cardiotonic steroid linked to Na⁺/K⁺-ATPase-mediated profibrotic signaling, collagen deposition, and vascular remodeling.
Clinical questions
How the platform is positioned.
Why MBG?
Elevated levels of marinobufagenin (MBG) are implicated in fibrosis, vascular dysfunction, and disease progression across multiple severe conditions.
Why extracorporeal?
Padakonn’s approach uses a Class IIb extracorporeal medical device designed to block MBG in the bloodstream while integrating with established extracorporeal treatment workflows and existing regulatory frameworks.
Why now?
Chronic kidney disease affects more than 850 million people worldwide and is projected to become the 5th leading cause of years of life lost by 2040. Despite the growing burden of fibrosis and cardiovascular complications, targeted approaches addressing MBG-associated disease mechanisms remain limited.
What is next, fibrosis?
A focused language map for clinicians, researchers and partners.
The core vocabulary follows the biology: MBG, CKD fibrosis, sodium pump signaling, vascular stiffness and extracorporeal neutralization.
MBG science
marinobufageninendogenous cardiotonic steroidsMBG signaling pathwayFli1 signalingcollagen-1 signaling
Nephrology
chronic kidney diseaseCKD fibrosisrenal fibrosishemodialysis technologyvascular stiffness in CKD
Therapeutics
anti-MBG monoclonal antibodyMBG immunoadsorptionfibrosis targeted therapyprecision nephrologyextracorporeal therapy
Clinical signals
MBG biomarkerpreeclampsia biomarkerendothelial dysfunctionhypertension signalingvascular remodeling
Team
Scientific and clinical leadership.
A cross-border team combining nephrology, clinical research, antibody biology and business development.
Alexei Bagrov, MD, PhD
Principal Investigator, Co-founder
Estonia / Israel / USA
David Adair, MD, PhD
Product Developer
USA
Olle Melander, MD, PhD
Researcher, R&D
Sweden
Mai Rosenberg, MD, PhD
Chief Clinical, Researcher
Estonia
Kirill Smirnov, MBA
Chief Business Officer, Co-founder
Estonia
Evidence base
Selected literature
Publications supporting the MBG, fibrosis and cardiovascular-risk thesis behind the platform.
- Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev. 2009. Source
- Endogenous cardiotonic steroids in chronic renal failure. Nephrol Dial Transplant. 2011. Source
- Antibody to Marinobufagenin reverses placenta-induced fibrosis of umbilical arteries in preeclampsia. Int J Mol Sci. 2018. Source
- Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists. J Hypertens. 2015. Source
- Antibody to endogenous cardiotonic steroid reverses vascular fibrosis and restores vasorelaxation in chronic kidney disease. Int J Mol Sci. 2024. Source
Inquiry
Start a focused conversation with Padakonn Pharma.
For investment research, scientific questions, translational partnerships, product diligence and media requests.
We route inquiries by topic and reply from the relevant team member.
For investor or partner materials, include your organization and the context of your request.